



Lentigen™

Lentigen Corporation Named Best Life Science Company in 7th Annual Maryland Incubator Company of the Year Awards

Baltimore, MD, June 20, 2007 – Lentigen Corporation, a privately held biotechnology company focused on the manufacturing and development of lentiviral vectors, announced today that it has been named Best Life Science Company in the 7th Annual Maryland Incubator Company of the Year Awards. Sponsored by Maryland Department of Business and Economic Development (DBED), the Maryland Technology Development Corporation (TEDCO), RSM McGladrey, Inc., and Saul Ewing LLP, the awards recognize the achievements of Maryland incubator companies representing a diverse cross-section of technologies and services.

“We are honored to have been selected among our accomplished peers in the life sciences for this award,” said Dr. Boro Dropulic, founder and CEO of Lentigen. “Our goal is to continue to earn recognition for our lentiviral vector gene delivery technology as we further develop its applications in biotechnology and medicine.”

Lentigen was one of 18 finalists for the awards, which are given in several categories by a selection committee of regional industry leaders and early-stage investors. “The entries for this year’s Incubator Company of the Year Awards were very impressive,” said Robert A. Spar, Esq., a partner at sponsor Saul Ewing. “We are proud to once again be involved in this awards program that acknowledges the high quality of work and valuable contributions that incubator companies are making in Maryland.”

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of Lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit www.Lentigen.com.

About Lentiviral Vectors

Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have been shown to achieve high, but not stable, gene delivery into cells or to deliver genes stably, but not efficiently (murine retroviral vectors).

Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating itself into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.

Contacts:

Lentigen Corporation
Greg Feulner, VP Business Development
443-543-5318
greg.feulner@lentigen.com

Media Contact:
Meghan Feeks
Richard Lewis Communications, Inc.
212-827-0020
mfeeks@rlcinc.com

Investor Contact:
Tara Spiess
TS Communications Group, LLC
914-921-5900
spiess@biotechirpr.com